SOD1-targeting therapies for neurodegenerative diseases: a review of current findings and future potential

References

• Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. 2017;3:17071.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;CD001447.
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Edaravone: a new drug approved for ALS. Cell. 2017;171(4):725.
   PubMed Web of Science ®Google Scholar
• Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–512.
   PubMed Web of Science ®Google Scholar
• Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109–119.
   PubMed Web of Science ®Google Scholar
• Mueller C, Berry JD, McKenna-Yasek DM, et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N Engl J Med. 2020;383(2):151–158.
   PubMed Web of Science ®Google Scholar
• Hardiman O, van den Berg LH. The beginning of genomic therapies for ALS. N Engl J Med NLM (Medline). 2020;383(2):180–181.
   PubMed Web of Science ®Google Scholar
• Zou ZY, Zhou ZR, Che CH, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540–549.
   PubMed Web of Science ®Google Scholar
• Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018;14(9):544–558.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81(12):1324–1326. .
   PubMed Web of Science ®Google Scholar
• Ferraiuolo L, Kirby J, Grierson AJ, et al. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:616–630.
   PubMed Web of Science ®Google Scholar
• Turner MR, Al-Chalabi A, Chio A, et al. Genetic screening in sporadic ALS and FTD. J. Neurol. Neurosurg. Psychiatry. BMJ Publishing Group; 2017;88. p. 1042–1044
   PubMed Web of Science ®Google Scholar
• Kuuluvainen L, Kaivola K, Mönkäre S, et al. Oligogenic basis of sporadic ALS: the example of SOD1 p.Ala90Val mutation. Neurol Genet. 2019;5(3):e335.
   Web of Science ®Google Scholar
• Crapo JD, Oury T, Rabouille C, et al. Copper,zinc superoxide dismutase is primarily a cytosolic protein in human cells. Proc Natl Acad Sci U S A. 1992;89(21):10405–10409.
   PubMed Web of Science ®Google Scholar
• Sturtz LA, Diekert K, Jensen LT, et al. A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J Biol Chem. 2001;276:38084–38089.
   PubMed Web of Science ®Google Scholar
• Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry. 2005;76(8):1046 LP– 1057.
   Web of Science ®Google Scholar
• Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta - Mol Basis Dis. 2006;1762(11–12):1051–1067.
   PubMed Web of Science ®Google Scholar
• Brown RH, van Zundert B, Brown RH. Silencing strategies for therapy of SOD1-mediated ALS. Neurosci Lett. 2017;636:32–39.
   PubMed Web of Science ®Google Scholar
• Deng HX, Hentati A, Tainer JA, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993;261(5124):1047–1051.
   PubMed Web of Science ®Google Scholar
• Lutz C. Mouse models of ALS: past, present and future. Brain Res. 2018;1693:1–10.
   PubMed Web of Science ®Google Scholar
• Saccon RA, Bunton-Stasyshyn RKA, Fisher EMC, et al. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain. 2013;136(8):2342–2358.
   PubMedGoogle Scholar
• Baskoylu SN, Yersak J, O’Hern P, et al. Single copy/knock-in models of ALS SOD1 in C. elegans suggest loss and gain of function have different contributions to cholinergic and glutamatergic neurodegeneration. PLoS Genet. 2018;14(10):e1007682.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Homma K, Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv Biol Regul. 2016;60:95–104.
   PubMedGoogle Scholar
• Hayward LJ, Rodriguez JA, Kim JW, et al. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J Biol Chem. 2002;277(18):15923–15931.
   PubMed Web of Science ®Google Scholar
• Borchelt DR, Lee MK, Slunt HS, et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci. 1994;91(17):8292–8296.
   PubMed Web of Science ®Google Scholar
• Bruijn LI. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science. 1998;281(5384):1851–1854.
   PubMed Web of Science ®Google Scholar
• Hayward C, Brock DJH, Minns RA, et al. Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J Med Genet. 1998:35(2):174. BMJ Publishing Group.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Nordström U, Tsiakas K, et al. Phenotype in an infant with SOD1 homozygous truncating mutation. N Engl J Med. 2019;381(5):486–488.
   PubMed Web of Science ®Google Scholar
• Broom WJ, Greenway M, Sadri-Vakili G, et al. 50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9(4):229–237.
   PubMed Web of Science ®Google Scholar
• Ip P, Mulligan VK, Chakrabartty A. ALS- causing SOD1 mutations promote production of copper-deficient misfolded species. J Mol Biol. 2011;409(5):839–852.
   PubMed Web of Science ®Google Scholar
• Sen Mojumdar S, SchollZ N, Dee DR, et al. Partially native intermediates mediate misfolding of SOD1 in single-molecule folding trajectories. Nat Commun. 2017;8(1):1881.
   PubMedGoogle Scholar
• Capper MJ, Wright GSA, Barbieri L, et al. The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation. Nat Commun. 2018;9(1):1963.
   Web of Science ®Google Scholar
• Benkler C, O’Neil AL, Slepian S, et al. Aggregated SOD1 causes selective death of cultured human motor neurons. Sci Rep. 2018;8(1):16393.
   PubMedGoogle Scholar
• Bidhendi EE, Bergh J, Zetterström P, et al. Two superoxide dismutase prion strains transmit amyotrophic lateral sclerosis–like disease. J Clin Invest. 2016;126(6):2249–2253.
   PubMed Web of Science ®Google Scholar
• Karch CM, Prudencio M, Winkler DD, et al. Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc Natl Acad Sci U S A. 2009;106:7774–7779.
   PubMed Web of Science ®Google Scholar
• Gill C, Phelan JP, Hatzipetros T, et al. SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS. Sci Rep. 2019;9:6724.
   PubMed Web of Science ®Google Scholar
• Lezi E, Swerdlow RH. Mitochondria in neurodegeneration. Adv ExMed Biol. 2012;942:269–286.
   PubMed Web of Science ®Google Scholar
• Tan W, Pasinelli P, Trotti D. Role of mitochondria in mutant SOD1 linked amyotrophic lateral sclerosis. Biochim Biophys Acta - Mol Basis Dis Elsevier. 2014;1842(8):1295–1301.
   PubMed Web of Science ®Google Scholar
• Ferri A, Cozzolino M, Crosio C, et al. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc Natl Acad Sci. 2006;103(37):13860–13865.
   PubMed Web of Science ®Google Scholar
• Kann O, Hollnagel J-O, Elzoheiry S, et al. Energy and potassium ion homeostasis during gamma oscillations. Front Mol Neurosci. 2016;9:47.
   PubMed Web of Science ®Google Scholar
• Israelson A, Arbel N, Da Cruz S, et al. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron. 2010;67(4):575–587.
   PubMed Web of Science ®Google Scholar
• Arbel N, Shoshan-Barmatz V. Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity. J Biol Chem. 2010;285(9):6053–6062.
   PubMed Web of Science ®Google Scholar
• Pasinelli P, Belford ME, Lennon N, et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 2004;43(1):19–30.
   PubMed Web of Science ®Google Scholar
• De Vos KJ, Grierson AJ, Ackerley S, et al. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci. 2008;31(1):151–173.
   PubMedGoogle Scholar
• Moller A, Bauer CS, Cohen RN, et al. Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels. Hum Mol Genet. 2017;26(23):4668–4679.
   PubMed Web of Science ®Google Scholar
• Nishitoh H, Kadowaki H, Nagai A, et al. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 2008;22(11):1451–1464.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in Motor Neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration. 1995;4(2):209–216.
   PubMedGoogle Scholar
• Vucic S, Kiernan MC. Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry. 2010;81:222–227.
   PubMed Web of Science ®Google Scholar
• Park SB, Kiernan MC, Vucic S. Axonal excitability in amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14:78–90.
   PubMed Web of Science ®Google Scholar
• Bae JS, Simon NG, Menon P, et al. The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol. 2013;9(2):65–74.
   PubMed Web of Science ®Google Scholar
• Kubat Öktem E, Mruk K, Chang J, et al. Mutant SOD1 protein increases Nav1.3 channel excitability. J Biol Phys. 2016;42(3):351–370.
   PubMed Web of Science ®Google Scholar
• Madji Hounoum B, Mavel S, Coque E, et al. Wildtype motoneurons, ALS-linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia. 2017;65:592–605.
   PubMed Web of Science ®Google Scholar
• Bonifacino T, Provenzano F, Gallia E, et al. In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2019;129:79–92.
   PubMed Web of Science ®Google Scholar
• Ferraiuolo L, Meyer K, Sherwood TW, et al. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc Natl Acad Sci U S A. 2016;113(42):E6496.
   PubMed Web of Science ®Google Scholar
• Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29(9):824–828.
   PubMed Web of Science ®Google Scholar
• Kang SH, Li Y, Fukaya M, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci. 2013;16(5):571–579.
   PubMed Web of Science ®Google Scholar
• Wang L, Gutmann DH, Roos RP. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum Mol Genet. 2011;20(2):286–293.
   PubMed Web of Science ®Google Scholar
• Boillee S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389–1392.
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59–62.
   PubMed Web of Science ®Google Scholar
• Ihara Y, Mori A, Hayabara T, et al. Superoxide dismutase and free radicals in sporadic amyotrophic lateral sclerosis: relationship to clinical data. J Neurol Sci. 1995;134(1–2):51–56.
   PubMed Web of Science ®Google Scholar
• Acworth IN, Bogdanov MB, McCabe DR, et al. Estimation of hydroxyl free radical levels in vivo based on liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl. 1997 Mar 28;691(1):23-32.
   Google Scholar
• Uchida K, Shiraishi M, Naito Y, et al. Activation of stress signaling pathways by the end product of lipid peroxidation. J Biol Chem. 1999;274(4):2234–2242.
   PubMed Web of Science ®Google Scholar
• Shaw PJ, Ince PG, Falkous G, et al. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol. 1995;38(4):691–695.
   PubMed Web of Science ®Google Scholar
• Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 1996;13(1):43–47.
   PubMed Web of Science ®Google Scholar
• Fischer LR, Li Y, Asress SA, et al. Absence of SOD1 leads to oxidative stress in peripheral nerve and causes a progressive distal motor axonopathy. ExNeurol. 2012;233:163–171.
   PubMed Web of Science ®Google Scholar
• Muller FL, Song W, Liu Y, et al. Absence of CuZn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy. Free Radic Biol Med. 2006;40(11):1993–2004.
   PubMed Web of Science ®Google Scholar
• Park JH, Elpers C, Reunert J, et al. SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis. Brain. 2019;142(8):2230–2237.
   PubMedGoogle Scholar
• Ayers JI, Xu G, Pletnikova O, et al. Conformational specificity of the C4F6 SOD1 antibody; low frequency of reactivity in sporadic ALS cases. Acta Neuropathol Commun. 2014;2(1):55.
   PubMedGoogle Scholar
• Leyton-Jaimes MF, Kahn J, Israelson A. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS. Proc Natl Acad Sci U S A. 2019;116(29):14755–14760.
   PubMed Web of Science ®Google Scholar
• Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. Elegans Cell. 1993;75(5):855–862.
   Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK-H, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008;19(1):92–105. Oct 27.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zheng S, Geng Y, et al. MicroRNA profiling of atrial fibrillation in canines: miR-206 modulates intrinsic cardiac autonomic nerve remodeling by regulating SOD1. Gupta S, editor. PLoS One. 2015;10(3):e0122674.
   PubMed Web of Science ®Google Scholar
• Di Pietro L, Baranzini M, Berardinelli MG, et al. Potential therapeutic targets for ALS: MIR206, MIR208b and MIR499 are modulated during disease progression in the skeletal muscle of patients. Sci Rep. 2017;7(1):9538.
   PubMedGoogle Scholar
• Toivonen JM, Manzano R, Oliván S, et al. MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS One. 2014;9(2):e89065.
   PubMed Web of Science ®Google Scholar
• Chery J. RNA therapeutics: rNAi and antisense mechanisms and clinical applications. Postdoc J a J Postdr Res Postdr Aff. 2016;4:35–50.
   PubMedGoogle Scholar
• Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441(7092):537–541.
   PubMed Web of Science ®Google Scholar
• Colella P, Ronzitti G, Mingozzi F. Emerging Issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev Cell Press. 2018;8: 87–104.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med. 2020;382(1):29–40. .
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Ding H, Schwarz DS, Keene A, et al. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell. 2003;2(4):209–217.
   PubMed Web of Science ®Google Scholar
• Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med. 2005;11(4):429–433.
   PubMed Web of Science ®Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun J-C, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med. 2005;11(4):423–428.
   PubMed Web of Science ®Google Scholar
• Foust KD, Salazar DL, Likhite S, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21(12):2148–2159.
   PubMed Web of Science ®Google Scholar
• Bravo-Hernandez M, Tadokoro T, Navarro MR, et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med. 2020;26(1):118–130.
   PubMed Web of Science ®Google Scholar
• Iannitti T, Scarrott JM, Likhite S, et al. Translating SOD1 Gene Silencing toward the Clinic: a Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS. Mol Ther Nucleic Acids. 2018;12:75–88.
   PubMedGoogle Scholar
• Borel F, Gernoux G, Sun H, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med. 2018;10(465):31.
   Web of Science ®Google Scholar
• Schoch KM, Miller TM. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron. 2017;94(6):1056–1070.
   PubMed Web of Science ®Google Scholar
• Younis HS, Vickers T, Levin AA, et al. CpG and non-CpG oligodeoxynucleotides induce differential proinflammatory gene expression profiles in liver and peripheral blood leukocytes in mice. J Immunotoxicol. 2006;3(2):57–68.
   PubMedGoogle Scholar
• Ly CV, Miller TM. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr Opin Neurol. 2018;31(5):648–654.
   PubMed Web of Science ®Google Scholar
• Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol Ther. 2017;25(5):1069–1075. American Society of Gene and Cell Therapy.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625–635.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–1732.
   PubMed Web of Science ®Google Scholar
• Bennett Frank C, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu Rev Neurosci. 2019;42(1):385–406.
   PubMedGoogle Scholar
• Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116(8):2290–2296.
   PubMed Web of Science ®Google Scholar
• Winer L, Srinivasan D, Chun S, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70(2):201–207.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435–442.
   PubMed Web of Science ®Google Scholar
• Scotton WJ, Mollan SP, Walters T, et al. Characterising the patient experience of diagnostic lumbar puncture in idiopathic intracranial hypertension: a cross-sectional online survey. BMJ Open. 2018;8(5):e020445.
   PubMed Web of Science ®Google Scholar
• Montes de Oca Delgado M, Cacho Díaz B, Santos Zambrano J, et al. The comparative treatment of intraventricular chemotherapy by ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis. Front Oncol. 2018;8:509.
   PubMed Web of Science ®Google Scholar
• Lake W, Shah H. Intrathecal baclofen infusion for the treatment of movement disorders. Neurosurg Clin N Am. 2019;30(2):203–209.
   PubMed Web of Science ®Google Scholar
• Jinek M, East A, Cheng A, et al. RNA-programmed genome editing in human cells. Elife. 2013;
   PubMed Web of Science ®Google Scholar
• Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–2308.
   PubMed Web of Science ®Google Scholar
• Jiang F, Doudna JA. CRISPR–Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46(1):505–529.
   PubMedGoogle Scholar
• Gaj T, Ojala DS, Ekman FK, et al. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv. 2017;3(12):eaar3952.
   PubMed Web of Science ®Google Scholar
• Qi LS, Larson MH, Gilbert LA, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–1183.
   PubMed Web of Science ®Google Scholar
• Kuscu C, Parlak M, Tufan T, et al. CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations. Nat Methods. 2017;14(7):710–712.
   PubMed Web of Science ®Google Scholar
• Lim CKW, Gapinske M, Brooks AK, et al. Treatment of a mouse model of ALS by in vivo base editing. Mol Ther. 2020;28(4):1177–1189.
   PubMedGoogle Scholar
• Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149-157.
   PubMed Web of Science ®Google Scholar
• Kieran D, Kalmar B, Dick JRT, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10(4):402–405.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90(7):e565–e574.
   PubMed Web of Science ®Google Scholar
• Lange DJ, Andersen PM, Remanan R, et al. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study. Amyotroph Lateral Scler Front Degener. 2013;14(3):199–204.
   PubMed Web of Science ®Google Scholar
• Lange DJ, Shahbazi M, Silani V, et al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann Neurol. 2017;81(6):837–848.
   PubMed Web of Science ®Google Scholar
• Tsuburaya N, Homma K, Higuchi T, et al. A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model. Nat Commun. 2018;9(1):2668.
   PubMedGoogle Scholar
• Hilton JB, Mercer SW, Lim NKH, et al. CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci Rep. 2017;7(1):42292.
   PubMedGoogle Scholar
• Hung LW, Villemagne VL, Cheng L, et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease. J Exp Med. 2012;209:837–854.
   PubMed Web of Science ®Google Scholar
• Roberts BR, Lim NKH, McAllum EJ, et al. Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2014;34(23):8021–8031.
   PubMed Web of Science ®Google Scholar
• Soon CPW, Donnelly PS, Turner BJ, et al. Diacetylbis(N (4)-methylthiosemicarbazonato) Copper(II) (Cu II (atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J Biol Chem. 2011;286(51):44035–44044.
   PubMed Web of Science ®Google Scholar
• Hilton JB, White AR, Crouch PJ. Metal-deficient SOD1 in amyotrophic lateral sclerosis. J Mol Med (Berl). 2015;93(5):481–487.
   PubMed Web of Science ®Google Scholar
• Farrawell NE, Yerbury MR, Plotkin SS, et al. CuATSM protects against the in vitro cytotoxicity of wild-type-like copper–zinc superoxide dismutase mutants but not mutants that disrupt metal binding. ACS Chem Neurosci. 2019;10(3):1555–1564.
   PubMed Web of Science ®Google Scholar
• DuVal MG, Hinge VK, Snyder N, et al. Tryptophan 32 mediates SOD1 toxicity in a in vivo motor neuron model of ALS and is a promising target for small molecule therapeutics. Neurobiol Dis. 2019;124:297–310.
   PubMed Web of Science ®Google Scholar
• Manjula R, Unni S, Wright GSA, et al. Rational discovery of a SOD1 tryptophan oxidation inhibitor with therapeutic potential for amyotrophic lateral sclerosis. J Biomol Struct Dyn. 2019;37(15):3936–3946.
   PubMed Web of Science ®Google Scholar
• Hirayama K, Fujiwara Y, Terada T, et al. Virtual screening identification of novel chemical inhibitors for aberrant interactions between pathogenic mutant SOD1 and tubulin. Neurochem Int. 2019;126:19–26.
   PubMed Web of Science ®Google Scholar
• Israelson A, Ditsworth D, Sun S, et al. Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. Neuron. 2015;86(1):218–232. .
   PubMed Web of Science ®Google Scholar
• Banerjee V, Oren O, Ben-Zeev E, et al. A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity. J Biol Chem. 2017;292(38):15777–15788.
   PubMed Web of Science ®Google Scholar
• Dagan B, Oren O, Banerjee V, et al. A hyperthermophilic protein G variant engineered via directed evolution prevents the formation of toxic SOD1 oligomers. Proteins Struct Funct Bioinforma. 2019;87(9):738–747.
   PubMed Web of Science ®Google Scholar
• Gros-Louis F, Soucy G, Larivière R, et al. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 2010;113:1188–1199.
   PubMed Web of Science ®Google Scholar
• Gros-Louis F, Soucy G, Larivière R, et al. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem. 2010;113:1188–1199.
   PubMed Web of Science ®Google Scholar
• Maier M, Welt T, Wirth F, et al. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci Transl Med. 2018;5;10(470).
   PubMed Web of Science ®Google Scholar
• Urushitani M, Ezzi SA, Julien J-P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2007;104(7):2495–2500.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Fujiwara N, Ido A, et al. Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol ExNeurol. 2010;69(10):1044–1056.
   PubMed Web of Science ®Google Scholar
• Ezzi SA, Urushitani M, Julien J-P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem. 2007;102(1):170–178.
   PubMed Web of Science ®Google Scholar
• Mackenzie IRA, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis withSOD1 mutations. Ann Neurol. 2007;61(5):427–434.
   PubMed Web of Science ®Google Scholar
• van Es MA, Dahlberg C, Birve A, et al. Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(5):562–566.
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Kaneko K, Yamanaka K, et al. Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis. J Biol Chem. 2008;283:24167–24176.
   PubMed Web of Science ®Google Scholar
• Tokuda E, Takei Y-I, Ohara S, et al. Wild-type Cu/Zn-superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis. Mol Neurodegener. 2019;14(1):42.
   PubMed Web of Science ®Google Scholar
• Bosco DA, Morfini G, Karabacak NM, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13(11):1396–1403.
   PubMed Web of Science ®Google Scholar
• Paré B, Lehmann M, Beaudin M, et al. Misfolded SOD1 pathology in sporadic amyotrophic lateral sclerosis. Sci Rep. 2018;8(1):14223.
   PubMedGoogle Scholar
• Medinas DB, Rozas P, Martínez Traub F, et al. Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2018 Jul 23;115(32):8209–8214.
   PubMed Web of Science ®Google Scholar
• Wang L, Deng H-X, Grisotti G, et al. Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse. Hum Mol Genet. 2009 Feb 19;18(9):1642–1651.
   PubMed Web of Science ®Google Scholar
• Guareschi S, Cova E, Cereda C, et al. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A. 2012;109(13):5074–5079.
   PubMed Web of Science ®Google Scholar
• Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015;16:564–574.
   PubMed Web of Science ®Google Scholar
• Bandmann O, Davis MB, Marsden CD, et al. Sequence of the superoxide dismutase 1 (SOD 1) gene in familial Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1995;59:90–91.
   PubMed Web of Science ®Google Scholar
• Trist BG, Davies KM, Cottam V, et al. Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson’s disease brain. Acta Neuropathol. 2017;134(1):113–127.
   PubMed Web of Science ®Google Scholar
• Trist BG, Fifita JA, Freckleton SE, et al. Accumulation of dysfunctional SOD1 protein in Parkinson’s disease is not associated with mutations in the SOD1 gene. Acta Neuropathol. 2018;135(1):155–156.
   PubMed Web of Science ®Google Scholar
• Ellett LJ, Hung LW, Munckton R, et al. Restoration of intestinal function in an MPTP model of Parkinson’s Disease. Sci Rep. 2016;6(1):30269.
   PubMedGoogle Scholar
• Southon A, Szostak K, Acevedo KM, et al. CuII (atsm) inhibits ferroptosis: implications for treatment of neurodegenerative disease. Br J Pharmacol. 2020;177(3):656–667.
   PubMed Web of Science ®Google Scholar
• Cheng L, Quek CYJ, Hung LW, et al. Gene dysregulation is restored in the Parkinson’s disease MPTP neurotoxic mice model upon treatment of the therapeutic drug CuII(atsm). Sci Rep. 2016;6(1):22398.
   PubMedGoogle Scholar
• Shaltouki A, Hsieh C-H, Kim MJ, et al. Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson’s models. Acta Neuropathol. 2018;136(4):607–620.
   PubMed Web of Science ®Google Scholar
• Hsieh C-H, Li L, Vanhauwaert R, et al. Miro1 marks Parkinson’s disease subset and miro1 reducer rescues neuron loss in Parkinson’s models. Cell Metab. 2019;30(1131–1140):e7.
   PubMedGoogle Scholar
• Dawson TM, Dawson VL. The role of parkin in familial and sporadic Parkinson’s disease. Mov Disord. 2010;25(S1):S32.
   PubMedGoogle Scholar
• Palomo GM, Granatiero V, Kawamata H, et al. Parkin is a disease modifier in the mutant SOD 1 mouse model of ALS. EMBO Mol Med. 2018;10(10).
   Web of Science ®Google Scholar